ICC to hear breast cancer drug dispute
A Los Angeles biopharmaceutical company has launched an ICC claim over a US$195 million licence agreement to promote a breast cancer drug in Greater China.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10